CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health | W81XWH 20 PRMRP TTDA COV

Opportunity Information: Apply for W81XWH 20 PRMRP TTDA COV

The CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health is a Department of Defense funding opportunity designed to push promising preclinical work toward real-world clinical products. It is explicitly product-driven, meaning proposals are expected to center on developing something that can be used in practice rather than generating basic science knowledge alone. The work must align with one or more Focus Areas identified under the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health, and it should clearly connect to health needs that matter to military Service members, Veterans, and other beneficiaries.

A key feature of this award is the emphasis on translation and near-term applicability. The supported "product" can take multiple forms. It may be a tangible medical countermeasure or tool, such as a drug, biologic, or medical device, but it can also be a knowledge-based product. In this program, a knowledge product is defined as a non-materiel deliverable built from evidence and research that is intended to transition into medical practice, training, clinical tools, or other solutions that support acquisition and sustainment of medical capabilities. In other words, the program recognizes that impactful solutions are not limited to hardware or therapeutics; they can also include structured clinical guidance, training systems, decision-support tools, or similar outputs that influence practice and behavior across the continuum of care, including prevention.

The opportunity expects applicants to start from a position where feasibility is already demonstrated. Proof of concept for the proposed product, or at least a prototype or preliminary version, should already exist before applying. Applications must include data that justify the approach and show why the product is likely to work; these supporting data can be unpublished and/or drawn from existing published literature. This requirement signals that the award is not intended for purely exploratory ideas, but rather for advancing candidates that have already cleared early technical risk and are ready for more rigorous development.

Another central requirement is a credible transition plan. The Principal Investigator must explain how the product will move to the next stage after the award period ends, such as progression into clinical trials, regulatory steps, or delivery to military and/or civilian markets. The transition plan is expected to include potential sources of follow-on funding and resources. Applicants are encouraged to build partnerships with industry or other funding organizations to strengthen the pathway to adoption, scale-up, and sustained impact beyond the life of the grant.

Administratively, this FY20 opportunity was released by the Department of Defense, Department of the Army, through USAMRAA under CFDA 12.420. The funding instrument type listed includes both cooperative agreements and grants, reflecting that some awards may involve closer collaboration or oversight depending on the project. Eligibility is described as unrestricted, meaning a wide range of organization types can apply, subject to any additional eligibility notes in the full announcement. The opportunity (W81XWH 20 PRMRP TTDA COV) was posted April 8, 2020, with an original closing date of June 12, 2020, and it anticipated making about four awards. The award ceiling is shown as 0 in the summary information, which typically indicates that applicants needed to refer to the full solicitation for detailed budget constraints or that the ceiling was not specified in the extracted summary.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 08, 2020.
• Applicants must submit their applications by Jun 12, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PRMRP TTDA COV

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: